▲ bullish
Impact
PhasePhase 2b (registrational)
Time to marketPotentially 2028-2029 if Phase 2b succeeds, given the registrational trial topline reads out in 2H 2027 and accelerated approval is possible via the C-peptide surrogate endpoint pathway
SAB-142 human anti-thymocyte globulin (hATG) Updated Jul 7
What to watch
SAB-142 is early-stage but has strong institutional validation and ample cash runway through 2028. The next major catalyst (Phase 2b topline data) is still over a year away, so near-term moves will be driven by enrollment milestones, conference data presentations, and progress on the PRISE-hATG study. The stock carries elevated short interest (~56-61% short ratio), so positive enrollment updates could trigger short squeezes. For investors, this is a pre-revenue binary bet with no near-term FDA decision, sizing accordingly is key.
Bull case
- Phase 1 data confirm C-peptide preservation (all 4 T1D participants), improved time-in-range from 73% to 85%, and a favorable safety profile, supports the biologic rationale
- Phase 2b SAFEGUARD is a registrational trial, positive data could directly support an FDA filing; FDA has confirmed C-peptide as a surrogate endpoint usable for accelerated approval
- Tzield's recent FDA accelerated approval (June 2026) for Stage 3 pediatric T1D de-risks the regulatory and commercial pathway for SAB-142 as the second disease-modifying T1D therapy
Bear case
- SAB-142 is the company's only pipeline asset, the stock is a single-drug binary outcome with no diversification if the Phase 2b fails
- Topline Phase 2b data not expected until 2H 2027, leaving a ~12-18 month gap with no near-term FDA catalyst, stock may drift or face dilution fears
- Tzield (Sanofi) already has first-mover advantage for Stage 3 pediatric T1D; Sanofi's commercial infrastructure is vastly larger than SAB's pre-commercial setup